Product Description: SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects[1][2][3].
Applications: Cancer-programmed cell death
Formula: C28H33ClN4O3
References: [1]Hammitzsch A, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73./[2]Tao J, Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomed Pharmacother. 2018 Oct;106:1727-1733./[3]Hay DA, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc. 2014 Jul 2;136(26):9308-19.
CAS Number: 1613695-14-9
Molecular Weight: 509.04
Compound Purity: 99.83
Research Area: Cancer; Inflammation/Immunology
Solubility: DMSO : 66.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Epigenetic Reader Domain;Histone Acetyltransferase
English
Deutsch
